PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24793808-5 2014 DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions. deoxynivalenol 0-3 interleukin 1 beta Mus musculus 57-65 16009389-4 2006 and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice. deoxynivalenol 48-51 interleukin 1 beta Mus musculus 82-90 25392278-0 2014 Role of tumor necrosis factor-alpha and interleukin-1beta in anorexia induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse. deoxynivalenol 125-139 interleukin 1 beta Mus musculus 40-57 25392278-3 2014 The purpose of this research was to determine the role of two proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in DON-induced anorexia. deoxynivalenol 165-168 interleukin 1 beta Mus musculus 133-150 25392278-3 2014 The purpose of this research was to determine the role of two proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in DON-induced anorexia. deoxynivalenol 165-168 interleukin 1 beta Mus musculus 152-160 25392278-6 2014 Oral exposure to DON at 5 mg/kg bw stimulated splenic and hepatic mRNA and plasma protein elevations of TNF-alpha and IL-1beta that corresponded to anorexia induction. deoxynivalenol 17-20 interleukin 1 beta Mus musculus 118-126 25392278-9 2014 Taken together, the results suggest that both TNF-alpha and IL-1beta play contributory role in anorexia induction following oral exposure to DON. deoxynivalenol 141-144 interleukin 1 beta Mus musculus 60-68 23791694-13 2013 After priming of the RAW 264.7 macrophage cell line with different TLR ligands, DON exposure differentially modulated IL-1beta, IL-10, and TNF-alpha production. deoxynivalenol 80-83 interleukin 1 beta Mus musculus 118-126 18433975-6 2008 The functional significance of elevated DON tissue concentrations was assessed by measuring IL-1beta, IL-6, and TNF-alpha mRNA responses in spleen, liver and lung. deoxynivalenol 40-43 interleukin 1 beta Mus musculus 92-100 9707511-10 1998 However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10. deoxynivalenol 14-16 interleukin 1 beta Mus musculus 171-179 15681167-5 2005 Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta). deoxynivalenol 0-14 interleukin 1 beta Mus musculus 79-87 15371230-7 2004 DON was found to induce the cytokines interleukin (IL)-1alpha, IL-1beta, IL-6 and IL-11. deoxynivalenol 0-3 interleukin 1 beta Mus musculus 63-71 9662416-0 1998 Modulation of IL-1beta, IL-6 and TNF-alpha secretion and mRNA expression by the trichothecene vomitoxin in the RAW 264.7 murine macrophage cell line. deoxynivalenol 94-103 interleukin 1 beta Mus musculus 14-22 12773775-0 2003 Role of IL-1(beta) in endotoxin potentiation of deoxynivalenol-induced corticosterone response and leukocyte apoptosis in mice. deoxynivalenol 48-62 interleukin 1 beta Mus musculus 8-18 12773775-4 2003 Coexposure to LPS (0.1 mg/kg, ip) plus DON (12.5 mg/kg, po) was found to significantly upregulate splenic IL-1beta mRNA and IL-1beta protein expression in B6C3F1 mice, as compared to treatments with vehicle or either of the toxins alone. deoxynivalenol 39-42 interleukin 1 beta Mus musculus 106-114 12773775-4 2003 Coexposure to LPS (0.1 mg/kg, ip) plus DON (12.5 mg/kg, po) was found to significantly upregulate splenic IL-1beta mRNA and IL-1beta protein expression in B6C3F1 mice, as compared to treatments with vehicle or either of the toxins alone. deoxynivalenol 39-42 interleukin 1 beta Mus musculus 124-132 12773775-11 2003 Taken together, the results indicate that IL-1beta is an important mediator of LPS plus DON-induced corticosterone and subsequent leukocyte apoptosis and, furthermore, this cytokine possibly acts through an ACTH-independent mechanism. deoxynivalenol 88-91 interleukin 1 beta Mus musculus 42-50 34209652-6 2021 We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression. deoxynivalenol 23-26 interleukin 1 beta Mus musculus 239-257 7597700-3 1995 Specifically, IL-1 beta and IL-6 mRNA levels increased in spleen and PP following exposure to VT. deoxynivalenol 94-96 interleukin 1 beta Mus musculus 14-23 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 170-173 interleukin 1 beta Mus musculus 182-190 31338007-2 2019 However, it is unknown whether DON stimulates IL-1beta expression through the activation of the nuclear factor-kappaB (NF-kappaB) pathway and the ACS/NLRP3 inflammasome. deoxynivalenol 31-34 interleukin 1 beta Mus musculus 46-54 31338007-4 2019 DON also upregulated IL-1beta expression from between 0.5 h and 6 h after treatment, and enhanced the nuclear localization of the NF-kappaB subunits, p50 and p65. deoxynivalenol 0-3 interleukin 1 beta Mus musculus 21-29 31338007-5 2019 NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. deoxynivalenol 90-93 interleukin 1 beta Mus musculus 102-110 31338007-5 2019 NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. deoxynivalenol 90-93 interleukin 1 beta Mus musculus 158-166 31338007-5 2019 NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. deoxynivalenol 144-147 interleukin 1 beta Mus musculus 102-110 31338007-5 2019 NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. deoxynivalenol 144-147 interleukin 1 beta Mus musculus 158-166 31338007-6 2019 In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. deoxynivalenol 78-81 interleukin 1 beta Mus musculus 33-41 31338007-6 2019 In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. deoxynivalenol 128-131 interleukin 1 beta Mus musculus 33-41 31338007-6 2019 In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. deoxynivalenol 128-131 interleukin 1 beta Mus musculus 141-149 31338007-6 2019 In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. deoxynivalenol 128-131 interleukin 1 beta Mus musculus 141-149 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 88-91 interleukin 1 beta Mus musculus 182-190 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 88-91 interleukin 1 beta Mus musculus 210-218 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 88-91 interleukin 1 beta Mus musculus 210-218 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 170-173 interleukin 1 beta Mus musculus 210-218 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 170-173 interleukin 1 beta Mus musculus 210-218 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 170-173 interleukin 1 beta Mus musculus 182-190 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 170-173 interleukin 1 beta Mus musculus 210-218 31338007-7 2019 Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. deoxynivalenol 170-173 interleukin 1 beta Mus musculus 210-218 31338007-8 2019 Collectively, the data suggested that DON induced IL-1beta expression in BV2 microglial cells through the activation of the NF-kappaB signaling pathway and the subsequent upregulation of the ASC/NLRP3 inflammasome. deoxynivalenol 38-41 interleukin 1 beta Mus musculus 50-58 31338007-9 2019 Therefore, DON may induce inflammatory diseases or disorders by activating IL-1beta expression. deoxynivalenol 11-14 interleukin 1 beta Mus musculus 75-83